Literature DB >> 20824462

Ethical aspects on rare diseases.

Luis A Barrera1, Gilberto Cely Galindo.   

Abstract

In this chapter we discuss several of the most relevant subjects related to ethics on Rare Diseases. Some general aspects are discussed such as the socio-psychological problems that confront the patients and their families that finally lead to marginalization and exclusion of patients affected by these diseases from the health programs, even in wealthy countries. Then we address problems related to diagnosis and some ethical aspects of newborn screening, prenatal, pre-implantation diagnosis and reference centers, as well as some conditions that should be met by the persons and institutions performing such tasks. Alternatives of solutions for the most critical situations are proposed. Subsequently the orphan drugs subject is discussed not only from the availability point of view, prizes, industrial practices, and purchasing power in developed and developing societies. The research related to rare disease in children and other especially vulnerable conditions, the need for informed consent, review boards or ethics comities, confidentiality of the information, biobanks and pharmacogenetics are discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20824462     DOI: 10.1007/978-90-481-9485-8_27

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  [Computer-assisted diagnosis of rare diseases].

Authors:  T Müller; A Jerrentrup; J R Schäfer
Journal:  Internist (Berl)       Date:  2018-04       Impact factor: 0.743

2.  Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review.

Authors:  Jaroslav Kacetl; Petra Marešová; Raihan Maskuriy; Ali Selamat
Journal:  Risk Manag Healthc Policy       Date:  2020-10-13

3.  Survey of healthcare experiences of Australian adults living with rare diseases.

Authors:  Caron Molster; Debra Urwin; Louisa Di Pietro; Megan Fookes; Dianne Petrie; Sharon van der Laan; Hugh Dawkins
Journal:  Orphanet J Rare Dis       Date:  2016-03-24       Impact factor: 4.123

4.  Mutations in TSPEAR, Encoding a Regulator of Notch Signaling, Affect Tooth and Hair Follicle Morphogenesis.

Authors:  Alon Peled; Ofer Sarig; Liat Samuelov; Marta Bertolini; Limor Ziv; Daphna Weissglas-Volkov; Marina Eskin-Schwartz; Christopher A Adase; Natalia Malchin; Ron Bochner; Gilad Fainberg; Ilan Goldberg; Koji Sugawara; Avital Baniel; Daisuke Tsuruta; Chen Luxenburg; Noam Adir; Olivier Duverger; Maria Morasso; Stavit Shalev; Richard L Gallo; Noam Shomron; Ralf Paus; Eli Sprecher
Journal:  PLoS Genet       Date:  2016-10-13       Impact factor: 5.917

5.  Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?

Authors:  R Rodriguez-Monguio; T Spargo; E Seoane-Vazquez
Journal:  Orphanet J Rare Dis       Date:  2017-01-05       Impact factor: 4.123

6.  Diagnosis of rare diseases under focus: impacts for Canadian patients.

Authors:  Daphne Esquivel-Sada; Minh Thu Nguyen
Journal:  J Community Genet       Date:  2017-07-21

Review 7.  Human germline genome editing is illegal in Canada, but could it be desirable for some members of the rare disease community?

Authors:  Erika Kleiderman; Ian Norris Kellner Stedman
Journal:  J Community Genet       Date:  2019-08-16

8.  Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).

Authors:  Se Hee Lee; Seung-Lai Yoo; Joon Seok Bang; Jong Hyuk Lee
Journal:  Int J Environ Res Public Health       Date:  2020-04-26       Impact factor: 3.390

9.  Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.

Authors:  Monika Wagner; Hanane Khoury; Jacob Willet; Donna Rindress; Mireille Goetghebeur
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.